ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0639

Delayed Diagnosis in Systemic Lupus Erythematosus

Romina Nieto1, Lucia Hernandez2, Nidia Noemí Merás3, Bordón Florencia Juliana4, Cintia Otaduy5, Lucila Garcia6, Rosa Serrano Morales7, Nicolás Pérez8, Micaela A. Cosatti9, Ana Carolina Montandon10, Gustavo Flores Chapacais11, Laissa C. Alves Alvino12, Emily Figuereido Neves13, Eloisa Bonfa14, Alexis Bondi Peralta15, Loreto Massardo16, Andrés Cadena Bonfanti17, Andrés Hormaza18, José Martínez19, Olga Lidia Vera Lastra20, Hilda Fragoso-Loyo21, ⁠Yaneli Juárez-Vicuña22, Diana Fernandez23, Patricia Langjarth24, Maria Teresa Martinez de Filartiga25, Manuel Ugarte-Gil26, Carlos Alejandro Loayza Flores27, Teresandris Polanco28, Maria Belen Lecumberri29, Álvaro Danza30, Carlos Enrique Toro-Gutierrez31, Urbano Sbarigia32, Ashley Orillion33, Federico Zazzetti34, Graciela Alarcon35, Bernardo Pons-Estel2 and Guillermo Pons-Estel36, and Grupo Latino Americano de Estudio del Lupus (GLADEL), 1Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 3Hospital Italiano de Córdoba, Cordoba, Argentina, 4Hospital Privado Universitario de Córdoba, Córdoba, Argentina, 5Hospital Córdoba, Cordoba, Spain, 6Servicio de Reumatología del HIGA San Martín, La Plata, Argentina, 7Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, 8Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, 9CEMIC Centro de Educación Médica e Investigaciones Clínicas ''Norberto Quirno'' CABA, CABA, Argentina, 10Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, 11Rheumatology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 12Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, 13Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, 14Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 15Hospital del Salvador, Santiago, Chile, 16Centro de Biología Celular y Biomedicina CEBICEM, Facultad de Medicina y Ciencias Universidad San Sebastián, Santiago, Chile, 17Universidad Simon Bolivar, Barranquilla, Colombia, 18Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 19Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, 20División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, 21Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 22Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología, Investigador en Ciencias Médicas C, Mexico City, Mexico, 23Member of GLADEL, Rosario, Argentina, 24Hospital de Clínicas I, Asunción, Paraguay, 25Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, 26Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, 27Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 28Hospital Docente Padre Billini, Santo Domingo, Dominica, 29Hospital Señor del Milagro, Salta, Argentina, 30Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, 31Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, 32Johnson & Johnson Innovative Medicine, Brussels, Belgium, 33Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 34Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 35The University of Alabama at Birmingham, Oakland, CA, 36Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina

Meeting: ACR Convergence 2024

Keywords: antiphospholipid syndrome, Cohort Study, Diagnostic criteria, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases; this also delays treatment initiation. Previous studies have reported that this delay in diagnosis is associated with a worse prognosis including higher disease activity, damage accrual, decreased quality of life and increased use of healthcare resources and, therefore, higher costs. In the GLADEL original cohort, a maximum time to SLE diagnosis of 24 months did not negatively influence disease outcomes (damage accrual and mortality)1. This study aimed to characterize delay in the diagnosis in SLE patients and its associated factors.

Methods: GLADEL 2.0 is an observational multi-ethnic, multi-national Latin-American SLE cohort. Forty-three centers from 10 Latin-American countries enrolled patients ≥18 years of age who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria. Patients were categorized into 4 subsets according to the presence or absence of active or inactive lupus nephritis (LN)2. Baseline demographics, clinical manifestations, disease activity (SLEDAI-2K) and SLICC/ACR damage index (SDI) and treatments were examined. Based on the original GLADEL report, variables were examined according to time to diagnosis shorter versus equal or longer than 24 months, as no impact was found on outcomes before this time1. Continuous variables are summarized as median (Q1, Q3) and categorical variables as counts and percentages. Logistic regression models were used to identify factors independently associated with a delay in diagnosis ≥24 months. P-values < 0.05 were considered significant. All analyses were done using R v4.4.0

Results: Of the 1083 patients included in this GLADEL cohort, 985 were included in these analyses. The remaining patients were excluded because of insufficient data for analysis. The median time to diagnosis was 8 months (0.27–5.67); in 97 patients (9.84%) the time to diagnosis was longer than 24 months. Table 1 depicts the sociodemographic and clinical characteristics of SLE patients according to time to diagnosis. Patients with a time to diagnosis greater than 24 months were found to be older at diagnosis, having a higher frequency of thrombocytopenia, associated comorbidities, antiphospholipid syndrome (APS), anti-B2GPI positivity and cumulative damage with lower frequency of low complement at cohort entry. After adjusting for sociodemographic, clinical and immunologic features, multivariate analysis showed that older age, middle socioeconomic status and associated APS were associated with a higher probability of diagnostic delay (Table 2).

Conclusion: In the GLADEL 2.0 multiethnic cohort, we found that delay in diagnosis was more likely to occur in older SLE patients and it was associated with APS. Future analyses will allow us to identify the impact of delayed diagnosis on outcome of SLE patients.

Reference:

1. Nieto R, et al. Lupus. 2024;33(4):340-346.
2. Gómez-Puerta JA, et al. Lupus. 2021;28:961203320988586.

Supporting image 1

Table 1

Supporting image 2

Table 2


Disclosures: R. Nieto: None; L. Hernandez: None; N. Merás: None; B. Juliana: None; C. Otaduy: None; L. Garcia: None; R. Serrano Morales: None; N. Pérez: None; M. Cosatti: None; A. Montandon: None; G. Chapacais: None; L. Alves Alvino: None; E. Figuereido Neves: AstraZeneca, 6; E. Bonfa: GlaxoSmithKlein(GSK), 5; A. Peralta: None; L. Massardo: None; A. Cadena Bonfanti: None; A. Hormaza: None; J. Martínez: None; O. Vera Lastra: None; H. Fragoso-Loyo: None; �. Juárez-Vicuña: None; D. Fernandez: None; P. Langjarth: None; M. Martinez de Filartiga: None; M. Ugarte-Gil: AstraZeneca, 1, 5, 6, Ferrer, 1, GlaxoSmithKlein(GSK), 5, 6, Janssen, 1; C. Loayza Flores: None; T. Polanco: None; M. Belen Lecumberri: None; Á. Danza: None; C. Toro-Gutierrez: None; U. Sbarigia: Janssen, 3, Johnson & Johnson, 11; A. Orillion: Janssen, 3, Johnson & Johnson, 11; F. Zazzetti: Janssen, 3, Johnson & Johnson, 11; G. Alarcon: None; B. Pons-Estel: AstraZeneca, 1, 6, GSK, 1, 6, Janssen, 1, 6; G. Pons-Estel: Abbvie, 6, AstraZeneca, 1, 6, 12, Support to attend a scientific event, Boehringer-Ingelheim, 1, 2, 6, 12, Support to attend a scientific event, GSK, 1, 5, 6, Janssen, 1, 5, 6, Novartis, 1, 6, 12, Support to attend a scientific event, Pfizer, 1, 6, Remegen, 1, RemeGen, 1, 2, Remegen, 2, RemeGen, 5, 6, Remegen, 6, Sanofi, 1, 2, 5, 6, Werfen Diagnostics, 1, 2, 5, 6.

To cite this abstract in AMA style:

Nieto R, Hernandez L, Merás N, Juliana B, Otaduy C, Garcia L, Serrano Morales R, Pérez N, Cosatti M, Montandon A, Chapacais G, Alves Alvino L, Figuereido Neves E, Bonfa E, Peralta A, Massardo L, Cadena Bonfanti A, Hormaza A, Martínez J, Vera Lastra O, Fragoso-Loyo H, Juárez-Vicuña �, Fernandez D, Langjarth P, Martinez de Filartiga M, Ugarte-Gil M, Loayza Flores C, Polanco T, Belen Lecumberri M, Danza Á, Toro-Gutierrez C, Sbarigia U, Orillion A, Zazzetti F, Alarcon G, Pons-Estel B, Pons-Estel G. Delayed Diagnosis in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/delayed-diagnosis-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/delayed-diagnosis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology